Disruption of the hexokinase-VDAC complex for tumor therapy

Oncogene

Volumn 27, Issue 34, 2008, Pages 4633-4635

  Galluzzi, L ^a,b,c   Kepp, O ^a,b,c   Tajeddine, N ^a,b,c   Kroemer, G ^a,b,c  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Apoptosis; Mitochondria; Voltage dependent anion channel (VDAC)

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; HEXOKINASE; JASMONIC ACID METHYL ESTER; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; VOLTAGE DEPENDENT ANION CHANNEL;

ANTINEOPLASTIC ACTIVITY; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; GLYCOLYSIS; MITOCHONDRIAL MEMBRANE; NONHUMAN; NOTE; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN INTERACTION; THROMBOCYTOPENIA; TUMOR CELL; TUMOR GROWTH;

ACETIC ACIDS; CYCLOPENTANES; HEXOKINASE; HUMANS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NEOPLASMS; OXYLIPINS; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN BINDING; VOLTAGE-DEPENDENT ANION CHANNELS;

EID: 49149087268     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.114     Document Type: Note

References (22)

1. Adams JM, Cory S. (2007). Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19: 488-496.
2. Alcala S, Klee M, Fernandez J, Fleischer A, Pimentel-Muinos FX. (2008). A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 27: 44-54.
3. Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL et al. (2003). Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92: 873-880.
4. Beutner G, Ruck A, Riede B, Brdiczka D. (1998). Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1368: 7-18.
5. Brenner C, Grimm S. (2006). The permeability transition pore complex in cancer cell death. Oncogene 25: 4744-4756.
6. Debatin KM, Poncet D, Kroemer G. (2002). Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21: 8786-8803.
7. Ferri KF, Kroemer G. (2001). Mitochondria - the suicide organelles. Bioessays 23: 111-115.
8. Galluzzi L, Larochette N, Zamzami N, Kroemer G. (2006). Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812-4830.
9. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T et al. (2008). Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene (this issue).
10. Jang JY, Choi Y, Jeon YK, Kim CW. (2008). Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10: R11.
11. Kroemer G, Galluzzi L, Brenner C. (2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163.
12. Kroemer G, Martin SJ. (2005). Caspase-independent cell death. Nat Med 11: 725-730.
13. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E et al. (2006). Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 66: 9143-9152.
14. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. (2007). Programmed anuclear cell death delimits platelet life span. Cell 128: 1173-1186.
15. Miyamoto S, Murphy AN, Brown JH. (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15: 521-529.
16. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
17. Pastorino JG, Hoek JB, Shulga N. (2005). Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545-10554.
18. Pedersen PL. (2007). Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg Effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211-222.
19. Robey RB, Hay N. (2006). Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25: 4683-4696.
20. Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H. (2008). Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol 28: 1007-1017.
21. Vieira HL, Belzacq AS, Haouzi D, Bernassola F, Cohen I, Jacotot E et al. (2001). The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene 20: 4305-4316.
22. Zamzami N, El Hamel C, Maisse C, Brenner C, Munoz-Pinedo C, Belzacq AS et al. (2000). Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene 19: 6342-6350.